- EMEA Innovative Medicine
- Collaborations
Our giving: organisations
Johnson & Johnson is fully committed to providing high quality products and services to healthcare professionals, patients and their families. Simply put, we always place the needs and well-being of the people we serve first. It is important for us to understand all aspects of patients’ needs. That’s why we engage and collaborate with patient organisations, who play an important role in informing, supporting, and assisting patients. As a company, we learn from this interaction, and that helps us in the development of new treatments and in providing useful information.
It is our goal to ensure that these relationships and partnerships proceed within a principled framework of mutual respect and learning, integrity, independence, and transparency.
This framework has been described in the “Code Of Practice On Relationships Between The Pharmaceutical Industry And Patient Organisations”, as developed by the European Federation Of Pharmaceutical Industry Associations (EFPIA) in collaboration with pan-European patient organisations.
Läbipaistvus koostöös patsiendiorganisatsioonidega
It is our goal to ensure that these relationships and partnerships proceed within a principled framework of mutual respect and learning, integrity, independence, and transparency.
This framework has been described in the “Code Of Practice On Relationships Between The Pharmaceutical Industry And Patient Organisations”, as developed by the European Federation Of Pharmaceutical Industry Associations (EFPIA) in collaboration with pan-European patient organisations.
Läbipaistvus koostöös patsiendiorganisatsioonidega
Our company adheres to these principles. Its key components are the following:
- The independence of patient organizations, in terms of their political judgment, policies and activities, will be assured.
- All partnerships between patient organisations and the pharmaceutical industry will be based on mutual respect, with the views and decisions of each partner having equal value.
- The pharmaceutical industry will not request, nor will patient organisations undertake, the promotion of a particular medicine.
- The objectives and scope of any partnership will be transparent. Financial and non- financial support provided by the pharmaceutical industry will always be clearly acknowledged.
- The pharmaceutical industry welcomes broad funding of patient organizations from multiple sources.
What is the nature of our collaboration with patient organisations?
J&J may interact with patient groups in the following ways:
- Support of educational programmes and conferences;
- Sponsorship of fund-raising events;
- Contributions to support programmes and services for the patient community and their care-givers;
- Contributions to support activities to help patients and care-givers advocate better treatment, services and support; and also collaborations to raise awareness about the diseases.
Below you will find an overview of the patient organizations that we support in Estonia
Name of the Patient Organisation | Website | Amount | Date of Contract |
Eesti Sclerosis Multiplex’i Ühingute Liit MTÜ | 5000 | 12 May 2016 | |
MTÜ Eesti Müeloomiliit | 1223 | 26 Oct 2016 | |
MTÜ Eesti Müeloomiliit | 1000 | 26 Oct 2016 | |
MTÜ Eesti Müeloomiliit | 2526.6 | 26 Oct 2016 | |
Eesti HIV-positiivsete Võrgustik | 500 | 30 Mar 2015 | |
MTÜ Eesti Müeloomiliit | 1221 | 11 May 2015 | |
Eesti Leukeemia- ja Lümfoomihaigete Liit | 961.5 | 16 Oct 2015 | |
MTÜ Eesti Müeloomiliit | 1000 | 16 Oct 2015 | |
MTÜ Eesti Vähiliit | 1000 | 11 Aug 2014 | |
MTÜ Eesti Müeloomiliit | 950 | 5 Sep 2014 | |
MTÜ Eesti Müeloomiliit | 2000 | 18 Sep 2014 | |
MTÜ Peaasjad | 2950 | 28 Nov 2014 | |
Estonian Network of PLWH (EHPV) | 500 | 1 Aug 2013 | |
Estonian Myeloma Society |
| 2000 | 13 Dec 2013 |